# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant B)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** B
**Date:** 2026-03-14T11:00:11.424553

---

**Idea Fidelity**

The submitted paper diverges materially from the original idea manifest. The manifest aimed to isolate the drug-market channel of EBT implementation by leveraging FBI Supplemental Homicide Reports (SHR) drug-related homicide codes and drug arrest data, seeking evidence of drug-market disruption through violence outcomes. Instead, the paper focuses on CDC drug-poisoning mortality and uses it as a proxy for drug-market activity. The identification strategy, outcome measures, and purported mechanism do not mirror the manifest: the key data sources (SHR, UCR arrest data) are absent, and the central research question—whether reduced cash supply disrupted drug-market violence—has been reframed as an investigation of overdose deaths. Consequently, the paper does not pursue the original idea as laid out in the manifest.

**Summary**

This paper studies the staggered implementation of EBT across U.S. states (1998–2004) and estimates its effect on state-level drug-poisoning mortality using Callaway–Sant’Anna DiD and TWFE specifications. The main result is a precisely estimated null effect, which the author interprets as evidence that disrupting the SNAP trafficking channel had no measurable impact on downstream overdose deaths, suggesting drug markets substituted away from paper benefit currency. Robustness checks, event studies, placebo outcomes, and sensitivity analyses support the claim of a null effect.

**Essential Points**

1. **Outcome choice and mechanism mismatch.** The paper argues that eliminating paper food stamps disrupted drug-market payment infrastructure, but evaluates this mechanism using drug-poisoning mortality, a downstream health outcome influenced by many supply- and demand-side forces (e.g., prescription opioid availability). The mapping from payment-infrastructure disruption to changes in overdose deaths is tenuous, and the paper lacks intermediate outcomes (e.g., drug availability, violence, trafficking arrests) that would more directly reflect the hypothesized channel. Without such evidence, the causal story is hard to substantiate.

2. **Construction of control group and pre-treatment balance.** The CS-DiD sample drops the 1998–1999 adopters due to lack of pre-treatment data, leaving only late adopters and not-yet-treated states. Yet, early adopters likely differ systematically (e.g., administrative capacity, baseline drug mortality trends), and excluding them raises concerns about external validity and the homogeneity assumption across cohorts. Moreover, the event-study admits a noisy $t=-5$ coefficient, and the Rambachan–Roth adjustment widens the confidence interval to include economically meaningful effects, undermining the strength of the null claim.

3. **Policy interpretation overreach.** The conclusion that “payment-infrastructure disruption” policies face fundamental limits is strong given the null on overdose deaths alone. Without showing that the specific funds trafficked via SNAP were significant relative to broader drug-market finance (or that other outcomes thought to respond directly to payment access also did not move), the causal link from EBT rollout to resilient drug markets remains speculative.

Given these issues, the paper requires substantial reworking before it can make a credible contribution on the causal effects of EBT on drug markets.

**Suggestions**

1. **Anchor the mechanism with more proximate outcomes.** To validate the causal link between EBT implementation and drug-market disruption, incorporate intermediate measures such as:
   - Drug-specific property or violent crime rates (e.g., from SHR “narcotics” circumstance codes) that directly capture market activity.
   - Drug-arrest or trafficking statistics (from UCR or other law enforcement datasets) that can reflect changes in law enforcement encounters related to cash transactions.
   - SNAP trafficking estimates (e.g., USDA audits) as a direct mediator between policy and market cash supply.

   Showing that these closer outcomes did not change would strengthen the claim that payment infrastructure disruption failed to shift market conditions, rather than assuming the absence of change from overdose mortality alone.

2. **Revisit the research question and framing.** If the primary contribution is the effect of EBT on health outcomes (drug poisoning deaths), the framing should acknowledge that the drug economy linkage is speculative unless additional evidence is offered. Alternatively, narrow the policy claim to what the data can speak to—namely, that EBT implementation coincided with no detectable change in overdose mortality—while being explicit about the limitations of interpreting this as a failure of payment-infrastructure disruption.

3. **Clarify identification and sample choices.**
   - Justify in more detail why states adopting EBT early (1998–1999) can be excluded without biasing the results. If their inclusion is infeasible due to data limitations, consider alternative approaches, such as synthetic control methods or borrowing national trends, to recover pre-treatment trends.
   - Provide balance tables or figures comparing early-adopting cohorts to late adopters on observable determinants of drug mortality. This would support the plausibility that adoption timing is as good as random conditional on fixed effects.
   - More explicitly report the number of treated and control observations at each event time in the event-study to give readers a sense of where the estimates are most precisely identified.

4. **Strengthen robustness and placebo strategy.** The robustness section relies mainly on TWFE specifications and the Rambachan–Roth sensitivity, but the null finding could benefit from:
   - Running the Callaway–Sant’Anna estimator on placebo outcomes (suicide, heart disease) to see if the design produces “effects” there, complementing the TWFE placebo table.
   - Exploring heterogeneous effects by cohort or by baseline trafficking intensity (if data on trafficking prevalence is available) to test whether certain states show any signal consistent with the mechanism.
   - Using alternative functional forms (e.g., Poisson models for counts of deaths) to ensure the result is not driven by the choice of linear rate models.

5. **Enhance discussion of null results.** Invest more effort interpreting the null in the context of statistical power and minimum detectable effects. For example:
   - Report the implied minimum detectable effect given the observed variance and sample size, so readers can assess what magnitudes are ruled out.
   - Discuss whether the null is consistent with theory: is it plausible that a 4-percent benefit diversion channel would be too small to move overdose mortality? If so, what does that imply for the broader policy relevance?
   - If possible, compare the estimated effect (and its confidence interval) to prior estimates of policy effects on drug homicide, arrests, or overdose rates, to situate the findings in the literature and calibrate their significance.

6. **Align conclusions with evidence.** The paper concludes that “payment infrastructure disruption policies face fundamental limits,” but this generalization should be tempered. Suggest rephrasing to emphasize that, in this case, EBT rollout did not generate detectable changes in drug-poisoning deaths, and that further research is needed to understand whether other aspects of payment flows or other contexts would behave similarly. If the paper retains the mechanism-oriented framing, add a subsection acknowledging alternative explanations (substitution, elasticity) and noting the limitations of inferring them from a null.

In summary, clarifying the mechanism, strengthening the identification, and tempering the policy conclusions would help this paper more convincingly address the causal impact of EBT on drug-related outcomes.
